Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-12-16EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
The EMA authorised Erelzi (etanercept) by Sandoz GmbH as a biosimilar to treat several inflammatory conditions including rheumatoid arthriti…
-
EMA approval · 2025-11-20EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
The EMA authorised Gobivaz (golimumab) for multiple inflammatory diseases. Indications include rheumatoid arthritis, juvenile idiopathic art…
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-10-16FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to t…
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.
-
EMA approval · 2025-10-13EMA Authorised: Ilaris (Canakinumab) — Novartis Europharm Limited
The EMA authorised Ilaris (canakinumab) for use in Cryopyrin-Associated Periodic Syndromes, juvenile idiopathic arthritis, and gout.
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
FDA approval · 2025-10-03FDA Approved: NAPROXEN — Original Application (Aurobindo Pharma Limited)
FDA approved Naproxen from Aurobindo Pharma Limited as an original generic application (ANDA 216504). Naproxen is a nonsteroidal anti-inflam…
-
EMA approval · 2025-10-02EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Tyenne (tocilizumab) by Fresenius Kabi Deutschland GmbH for multiple indications, including rheumatoid arthritis, juvenile id…
-
FDA approval · 2025-09-17FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental BLA for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited. The action concerns regulatory approval rel…
-
EMA approval · 2025-08-13EMA Authorised: Enbrel (etanercept) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Enbrel (etanercept) for multiple inflammatory diseases including rheumatoid arthritis, ankylosing s…
-
FDA approval · 2025-07-29FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Sandoz Inc for the adalimumab biosimilar ADALIMUMAB-ADAZ, enabling its use with indications cons…
-
FDA approval · 2025-07-29FDA Approved: VYSCOXA — Original Application (Carwin Pharmaceutical Associates, LLC)
FDA approved VYSCOXA, a brand name for celecoxib, under Carwin Pharmaceutical Associates, LLC's original application. This confirms marketin…
-
EMA approval · 2025-07-17EMA Authorised: Nordimet (methotrexate) — Nordic Group B.V.
EMA authorised Nordimet (methotrexate) by Nordic Group B.V. for use in arthritis-related conditions including rheumatoid arthritis, psoriati…
-
FDA approval · 2025-06-05FDA Approved: XIFYRM — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved XIFYRM (meloxicam) under an original application by Azurity Pharmaceuticals, Inc., establishing a new branded meloxicam product…
-
EMA approval · 2025-05-19EMA Authorised: Orencia (abatacept) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Orencia (abatacept) by Bristol-Myers Squibb Pharma EEIG for rheumatoid arthritis, psoriatic arthritis, and juvenile idiop…
-
FDA approval · 2025-05-12FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-azg) from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-04-07FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
FDA approved a supplemental application for ADALIMUMAB-AATY, a biosimilar adalimumab from Celltrion USA, Inc., in connection with its regula…
-
EMA approval · 2025-03-03EMA Authorised: Nepexto (etanercept) — Biosimilar Collaborations Ireland Limited
EMA authorised Nepexto, a biosimilar of etanercept, developed by Biosimilar Collaborations Ireland Limited, for several inflammatory arthrit…
-
FDA approval · 2025-02-21FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer, updating the extended-release formulation's label.
-
FDA approval · 2025-02-15FDA Approved: NAPROXEN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Naproxen (ANDA074190) from Hikma Pharmaceuticals USA Inc., resulting in an updated approval of t…
-
FDA approval · 2024-12-19FDA Approved: CELECOXIB — Supplemental Application (Aurobindo Pharma Limited)
FDA supplemental approval for Aurobindo Pharma Limited's generic celecoxib.
-
FDA approval · 2024-12-18FDA Approved: IDACIO — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for IDACIO (adalimumab-aacf) from Fresenius Kabi USA, LLC.